Scientific publications
Scientific publications
Preventive Cancer Vaccine Based on Neoantigens Gets Put to the Test
Studying the vaccine in dogs could give insight into its effectiveness in people…
Production of high-complexity frameshift neoantigen peptide microarrays
This report suggests that it is possible to produce hundreds to thousands of reproducible FS peptide microarrays that could enable cancer neoantigen discovery…
Antibody characterization using immunosignatures
A Comparison of a DNA Sourced Neoantigen Vaccine to an RNA Frameshift Vaccine in the Mouse Ovarian Cancer Model
Tumor bearing mice produce antibodies anti-Fs specific that can be detected by peptide microarray…
RNA transcription and Splicing errors as a Source of cancer frameshift neoantigens for Vaccines
Calviri is banking on their novel vaccine approach to stop cancer.Their study of RNA processing errors in tumors highlighted that a large number of frameshift neoantigens are produced. This new class of cancer neoantigens are shown in pre-clinical models to serve as protective vaccine components…
FAST vaccines based on frameshift neoantigens may have advantages over personal vaccines
The FAST technology may open new opportunities to develop a low cost, feasible and efficacious vaccine against cancer. Personalized and tumor-specific FS vaccines could protect against primary and metastatic lesions in a preclinical mouse model of breast cancer, inducing a potent T cell immune response…
Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening
This study introduces the frameshift peptide (FSP) array as a discovery platform for protective cancer neoantigens. Frameshift arrays are shown to be effective for functionally screening possible errors made by tumors at the RNA, not DNA, level for those that generate antibody-reactive neoantigens. Reactive FSPs selected from the array protect vaccinated mice from tumor challenge while non-reactive peptides do not.
Abstract, A simple blood based test for predicting clinical benefit of cancer immunotherapy
The FSPs with positive IgG reactive in response patients may be related to anti-tumor immune response, which needs to be further investigated. We also showed that the FSP array can potentially predict the patients who may have high grade immune related adverse events with the CPI treatment…
Common neoantigens from the frame shifted transcripts
This model predicts that these FS varients will be encoded in the RNA but not the DNA, most would be immunogenic and could serve as a vaccine component. Here we have tested each of these predictions using data from mice, dogs and humans…
Use of random peptide array to discover cancer neo antigens for vaccines and diagnostics
Neo-antigens from predicted fusion transcripts are targets of cancer humoral immune response. This work indicates that we can efficiently decipher neo-antigens from the immunosignatures of cancer subjects. This may be a new source of antigens for diagnosis and cancer vaccines
The immunosignature of canine lymphoma: characterization and diagnostic application
Immunosignatures can predict vaccine efficacy
Feasibility of an early Alzheimer’s disease immunosignature diagnostic test
Application of Immunosignatures to the Assessment of Alzheimer’s Disease